Client Profile

European investment fund focused in the medical and life science that was seeking to invest in a drug platform opportunity.

---

Resource Allocation

Destum Partners leveraged several resources to achieve our clients goals:
• Secondary Market Research: Extensive literature review, public domain analysis and syndicated data review
• Valuation: Market and Transaction Comparables
• Internal Expertise: Several consulting projects completed in CNS and Neuroscience fields that were of relevance our Client

Summary and Results

Destum Partners was engaged to create a due diligence report and asset monetization plan through the completion of a comprehensive analysis designed to increase the probability of a successful exit.

Destum began the DD process by completing a comprehensive review of all available materials related to R&D, pre-clinical & clinical studies, IP, management team, & other critical segments. Through the analysis, Destum was able to isolate areas of potential risk and develop a roadmap to strategically guide R&D and corporate activities (prioritized for potential future capital deployment). Transaction comparable analysis was completed to align the development roadmap with potential timing for securing a strategic partner and full exit. Destum’s analysis weighed the scientific / technical risks of the assets against market forces. We developed an investment strategy that focused allocation of capital towards key activities to advance the assets to key value inflection points.

The final deliverable contained actionable recommendations that our Client used to make a final a go / no-go investment decision.

Client Profile

Publicly traded Canadian biotech company developing first-in-class small molecules focused on epigenetics targets to treat cardiovascular disease.

---

Resource Allocation

Destum Partners leveraged several resources to achieve our clients goals:
• Primary Market Research: KOLs and payers were interviewed to determine the unmet medical need, the gap fill based on the TPP, potential use and drug pricing with reimbursement considerations
• Internal Expertise: Several consulting projects completed in the cardiovascular field

Summary and Results

Several primary market research studies have been completed for our Client testing their target product profile with a variety of physician types including cardiologist, endocrinologist, nephrologists and Neurologists. Payor primary and secondary market research studies have been completed to determine the core cost benefit drivers and a price range with a high likelihood of reimbursement.

Destum Partners used the result of the market research studies to build a business case and determine the asset potential for our client, based on indication, and prescriber group. In addition, the primary market research studies informed strategic development considerations from a patient stratification perspective and clinical end-point perspective. A commercial strategy was developed for the various indications evaluated and covered relevant material from commercial infrastructure, positioning, and marketing strategy and tactics.

The outputs of asset potential, product development and commercial strategy were used by our Client to help secure USD 50M in funding for further development of their drug.

Client Profile

Publicly traded German biotech company developing first-in-class Peptides in the Respiratory, Ophthalmology, Autoimmune and Hematology therapeutic areas.

---

Resource Allocation

Destum Partners leveraged several resources to achieve our clients goals:
• Primary Market Research: KOLs were interviewed to validate positioning strategy
• Secondary Market Research: Extensive literature review, public domain analysis and syndicated data synthesis occurred
• Valuation: Risk adjusted net present value ( rNPV ) methodology & transaction comps
• Internal Expertise: Several consulting projects completed in the therapeutic areas of interest to our Client

Summary and Results

Destum was engaged to select the optimal asset/indication strategy to reach key value inflection points & identify pathways to strategically deploy capital maximize the portfolio value.

The first phase involved Destum embarking on an extensive literature review of 35 potential indications. Emphasis was placed on differentiation of our Clients technology, target & disease biology, and clinical & commercial viability. Destum created a unique asset prioritization matrix to evaluate and rank all possible options. Destum’s analysis resulted in selecting three (3) programs with a total of 8 indications which were further assessed.

The second phase focused on formulating a TPP for each indication, identifying a positioning strategy, developing a granular clinical development plan (trial design & costs), and commercial forecast. Destum‘s customized rNPV valuation model was designed to isolate key value inflection points and correlate capital deployment with ROI.

Destum Partners strategic recommendations were accepted by our Client & their BOD; the final deliverable continues to serve as a core driver guiding our Clients corporate strategy.